Cladribine
Cladribine is an active ingredient of the class «Purine analogue».
Pharmaceutical drug
Boxed warning (US label)
Malignancies and risk of teratogenicity. Malignancies Treatment with MAVENCLAD may increase the risk of malignancy. MAVENCLAD is contraindicated in patients with current malignancy.
What it is used for
- Multiple sclerosis
- Hairy cell leukemia
- Lymphosarcoma
- Chronic lymphocytic leukemia
- Neoplasm
- Immune disorder
- Anemia
MAVENCLAD is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults.
Litak is indicated for the treatment of hairy-cell leukaemia.
How it works
- DNA inhibitor
Class: Purine analogue
Common side effects
The following serious adverse reactions and potential risks are discussed, or discussed in greater detail, in other sections of the labeling: Malignancies Risk of Teratogenicity Lymphopenia Infections Hematologic Toxicity Graft-Versus-Host Disease With Blood Transfusion Liver Injury Hypersensitivity Cardiac Failure…
Who should not take it
MAVENCLAD is contraindicated: in patients with current malignancy. in pregnant women and in females and males of reproductive potential who do not plan to use effective contraception during MAVENCLAD dosing and for 6 months after the last dose in each…
Pregnancy and breastfeeding
MAVENCLAD is contraindicated in pregnant women and in females and males of reproductive potential who do not plan to use effective contraception.
Interactions
- Ciclosporin
- Dipyridamole
- Eltrombopag
- Lamivudine
- Nifedipine
- Ribavirin
- Rifampicin
- Ritonavir
- Stavudine
- Zidovudine
Brand names
United States
Leustatin · Mavenclad
European Union
Litak · Mavenclad
Canada
Apo-Cladribine · Auro-Cladribine · Mavenclad
Other trade names
Leustat
Approval status
- US Food and Drug Administration
- prescription · since 1993
- European Medicines Agency
- authorised · since 2004
- Health Canada
- prescription · marketed
- First approval anywhere
- 1993
Codes
- ATC
- L01BB04, L04AA40
- RxNorm CUI
- 44157
- ChEMBL
- CHEMBL1619
- PubChem CID
- 20279
- UNII
- 47M74X9YT5
- Wikidata
- Q414030
Frequently asked questions
What is Cladribine used for?
Cladribine is used for: Multiple sclerosis, Hairy cell leukemia, Lymphosarcoma, Chronic lymphocytic leukemia, Neoplasm, Immune disorder, and Anemia.
What kind of medicine is Cladribine?
Cladribine is an active ingredient of the class «Purine analogue».
What are the brand names of Cladribine?
Brand names of Cladribine include Leustatin, Mavenclad, Litak, Apo-Cladribine, Auro-Cladribine, and Leustat.
Medicines in the same class
- Mercaptopurine
- Sirolimus
- Adalimumab
- Everolimus
- Leflunomide
- Fingolimod
- Apremilast
- Teriflunomide
- Tofacitinib
- Mycophenolate mofetil
Sources and licences
- ChEMBL (CC BY-SA 3.0)
- Wikidata (CC0 1.0)
- openFDA / DailyMed (public domain)
- European Medicines Agency (reuse with acknowledgement)
- Health Canada Drug Product Database (Open Government Licence – Canada)